patents.google.com

PT1088824E - BLYCYLIC PYRROLYL-AMIDES AS GLYCOGENE-PHOSPHORYLASE INHIBITORS - Google Patents

  • ️Fri Apr 30 2004

PT1088824E - BLYCYLIC PYRROLYL-AMIDES AS GLYCOGENE-PHOSPHORYLASE INHIBITORS - Google Patents

BLYCYLIC PYRROLYL-AMIDES AS GLYCOGENE-PHOSPHORYLASE INHIBITORS

Info

Publication number
PT1088824E
PT1088824E PT00308131T PT00308131T PT1088824E PT 1088824 E PT1088824 E PT 1088824E PT 00308131 T PT00308131 T PT 00308131T PT 00308131 T PT00308131 T PT 00308131T PT 1088824 E PT1088824 E PT 1088824E Authority
PT
Portugal
Prior art keywords
blycylic
glycogene
pyrrolyl
amides
phosphorylase inhibitors
Prior art date
1999-09-30
Application number
PT00308131T
Other languages
Portuguese (pt)
Inventor
Daisy Joe
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1999-09-30
Filing date
2000-09-18
Publication date
2004-04-30
2000-09-18 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
2004-04-30 Publication of PT1088824E publication Critical patent/PT1088824E/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

This invention relates to compounds of Formula I <CHEM> or stereoisomers, pharmaceutically acceptable salts or prodrugs thereof or a pharmaceutically acceptable salts of the prodrugs. This invention also relates to pharmaceutical compositions comprising a compound of Formula I, and to methods of treatment of diabetes, insulin resistance, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, cataracts, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemia, hyperlipidemia, atherosclerosis, or tissue ischemia.

PT00308131T 1999-09-30 2000-09-18 BLYCYLIC PYRROLYL-AMIDES AS GLYCOGENE-PHOSPHORYLASE INHIBITORS PT1088824E (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15714899P 1999-09-30 1999-09-30

Publications (1)

Publication Number Publication Date
PT1088824E true PT1088824E (en) 2004-04-30

Family

ID=22562529

Family Applications (1)

Application Number Title Priority Date Filing Date
PT00308131T PT1088824E (en) 1999-09-30 2000-09-18 BLYCYLIC PYRROLYL-AMIDES AS GLYCOGENE-PHOSPHORYLASE INHIBITORS

Country Status (10)

Country Link
US (3) US6399601B1 (en)
EP (1) EP1088824B1 (en)
JP (1) JP3489819B2 (en)
AT (1) ATE257480T1 (en)
BR (1) BR0004582A (en)
CA (1) CA2321379A1 (en)
DE (1) DE60007592T2 (en)
DK (1) DK1088824T3 (en)
ES (1) ES2211454T3 (en)
PT (1) PT1088824E (en)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU757748B2 (en) 1997-11-14 2003-03-06 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
US7223725B1 (en) * 1997-11-14 2007-05-29 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
EP1220672B1 (en) * 1999-10-12 2006-10-04 Lilly Icos LLC Medicament for treatment of neuropathies
CO5271699A1 (en) * 2000-01-24 2003-04-30 Pfizer Prod Inc PROCEDURE FOR THE TREATMENT OF CARDIOMIOPATIA USING INHIBITORS OF THE GLUCOGENO FOSFORILASA
AU2001241168B2 (en) * 2000-03-17 2005-06-16 Ajinomoto Co., Inc. Drugs for complications of diabetes and neuropathy and utilization thereof
EP1136071A3 (en) * 2000-03-22 2003-03-26 Pfizer Products Inc. Use of glycogen phosphorylase inhibitors
CN1446084A (en) * 2000-08-11 2003-10-01 辉瑞大药厂 Treatment of insulin resistance syndrome
US20020165237A1 (en) * 2000-08-11 2002-11-07 Fryburg David Albert Treatment of the insulin resistance syndrome
GB0021831D0 (en) * 2000-09-06 2000-10-18 Astrazeneca Ab Chemical compounds
NZ519752A (en) 2000-10-20 2005-04-29 Amylin Pharmaceuticals Inc Treatment of hibernating myocardium and diabetic cardiomyopathy with a GLP-1 peptide
AU2002226633A1 (en) * 2001-02-02 2002-08-12 Pfizer Limited Treatment of diabetes mellitus using vardenafil
EP1419771A4 (en) * 2001-08-23 2004-11-03 Mitsubishi Pharma Corp PROPHYLACTIC AND / OR CURATIVE AGENT FOR DISEASES INDUCED BY ARTERIOSCLEROSIS ACTIVITY
CA2465382A1 (en) * 2001-10-29 2003-05-08 Japan Tobacco Inc. Indole compound and medicinal use thereof
WO2003059372A2 (en) * 2001-12-29 2003-07-24 Novo Nordisk A/S Combined use of a glp-1 compound and a modulator of diabetic late complications
GB0205170D0 (en) * 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) * 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
JPWO2003091213A1 (en) * 2002-04-25 2005-09-02 アステラス製薬株式会社 Novel amide derivative or salt thereof
US7057046B2 (en) 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
US20040038864A1 (en) * 2002-06-27 2004-02-26 Per Balschmidt Use of dimethyl sulfone as isotonicity agent
JP4596915B2 (en) 2002-09-06 2010-12-15 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine H4 receptor ligands
GB0222909D0 (en) 2002-10-03 2002-11-13 Astrazeneca Ab Novel process and intermediates
GB0222912D0 (en) 2002-10-03 2002-11-13 Astrazeneca Ab Novel process and intermediates
JP2006507294A (en) * 2002-11-07 2006-03-02 ファイザー・プロダクツ・インク Antidiabetic
US7098235B2 (en) 2002-11-14 2006-08-29 Bristol-Myers Squibb Co. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
AU2003280767A1 (en) * 2002-11-14 2004-06-03 Ono Pharmaceutical Co., Ltd. Remedies for vertebral canal stenosis
WO2004050115A2 (en) * 2002-12-03 2004-06-17 Novo Nordisk A/S Combination treatment using exendin-4 and thiazolidinediones
JP2006519229A (en) * 2003-02-13 2006-08-24 アルバート・アインシュタイン・カレッジ・オヴ・メディシン・オヴ・イェシヴァ・ユニヴァーシティ Regulation of food intake and glucose production by modulation of long-chain fatty acyl-CoA levels in the hypothalamus
AU2004230316A1 (en) * 2003-04-15 2004-10-28 Pfizer Inc. Alpha substituted carboxylic acid as PPAR modulators
CA2522225A1 (en) * 2003-04-17 2004-10-28 Pfizer Products Inc. Carboxamide derivatives as anti-diabetic agents
MXPA05011702A (en) * 2003-04-30 2006-01-23 Pfizer Prod Inc Anti-diabetic agents.
US7405210B2 (en) * 2003-05-21 2008-07-29 Osi Pharmaceuticals, Inc. Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
UA84146C2 (en) * 2003-05-21 2008-09-25 Прозидион Лимитед Amides of pyrrolopyridine-2-carboxylic acid as inhibitors of glycogen phosphorylase, method for their synthesis, drug formulation, and their use as therapeutic agents
WO2004113345A1 (en) * 2003-06-20 2004-12-29 Japan Tobacco Inc. Fused pyrrole compound and medicinal use thereof
KR20060128976A (en) 2003-12-29 2006-12-14 세프라코 아이엔시. Pyrrole and pyrazole dieio inhibitors
DE602005023965D1 (en) 2004-03-08 2010-11-18 Prosidion Ltd PYRROLOPYRIDINE-2-CARBOXYLIC HYDRAZIDE AS INHIBITORS OF GLYCOPE PHOSPHORYLASE
WO2005115379A2 (en) * 2004-05-24 2005-12-08 New York University Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
US9737511B2 (en) * 2004-05-24 2017-08-22 Geoffrey C. GURTNER Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
WO2006041922A2 (en) * 2004-10-08 2006-04-20 Dara Biosciences, Inc. Agents and methods for administration to the central nervous system
US7365061B2 (en) 2004-11-15 2008-04-29 Bristol-Myers Squibb Company 2-Amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US7223786B2 (en) 2004-11-15 2007-05-29 Bristol-Myers Squibb Company 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors
WO2006055462A1 (en) 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US7214704B2 (en) 2004-11-15 2007-05-08 Bristol-Myers Squibb Company 2-Amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US20090298745A1 (en) * 2004-12-02 2009-12-03 Gerard Hugh Thomas Treatment of Diabetes with Glycogen Phosphorylase Inhibitors
KR20070102694A (en) * 2005-01-31 2007-10-19 아지노모토 가부시키가이샤 Pharmaceutical composition for improving or treating hyperglycemia, borderline diabetes, insulin resistance and hyperinsulinemia containing hypoglycemic agents
WO2006088875A2 (en) * 2005-02-14 2006-08-24 Albert Einstein College Of Medicine Of Yeshiva University Intranasal administration of modulators of hypothalamic atp-sensitive potassium channels
CN101553217A (en) 2005-07-06 2009-10-07 塞普拉科公司 Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment
US8053603B2 (en) 2006-01-06 2011-11-08 Sunovion Pharmaceuticals Inc. Tetralone-based monoamine reuptake inhibitors
CA2636324C (en) 2006-01-06 2012-03-20 Sepracor Inc. Cycloalkylamines as monoamine reuptake inhibitors
CA2648121C (en) 2006-03-31 2013-08-06 Sepracor Inc. Preparation of chiral amides and amines
PE20080251A1 (en) 2006-05-04 2008-04-25 Boehringer Ingelheim Int USES OF DPP IV INHIBITORS
US7579370B2 (en) * 2006-06-30 2009-08-25 Sepracor Inc. Fused heterocycles
US7884124B2 (en) 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
BRPI0713216A2 (en) * 2006-06-30 2012-12-04 Sepracor Inc fused heterocyclic d-amino acid oxidase inhibitors
US20080058395A1 (en) * 2006-06-30 2008-03-06 Sepracor Inc. Fused heterocyclic inhibitors of D-amino acid oxidase
JP5306818B2 (en) * 2006-10-18 2013-10-02 武田薬品工業株式会社 Fused heterocyclic compounds
US7902252B2 (en) 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
JP2010516697A (en) * 2007-01-18 2010-05-20 セプラコール インク． D-amino acid oxidase inhibitor
KR101581289B1 (en) 2007-05-31 2015-12-31 세프라코 아이엔시. Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors
US20100120740A1 (en) * 2008-08-07 2010-05-13 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
US10098857B2 (en) 2008-10-10 2018-10-16 The Board Of Trustees Of The Leland Stanford Junior University Topical and transdermal delivery of HIF-1 modulators to prevent and treat chronic wounds
US20100152200A1 (en) * 2008-11-17 2010-06-17 The Regents Of The University Of Michigan Alphavirus inhibitors and uses thereof
WO2011017634A2 (en) * 2009-08-07 2011-02-10 Sepracore Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
US20150050371A1 (en) 2012-03-09 2015-02-19 Biotropics Malaysia Berhad Extract Formulations of Rhodamnia Cinerea And Uses Thereof
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
GB201708451D0 (en) * 2017-05-26 2017-07-12 Univ Oxford Innovation Ltd Inhibitors of metallo-beta-lactamases
US11331288B2 (en) 2017-09-14 2022-05-17 The Board Of Trustees Of The Leland Stanford Junior University Conditioning irradiated tissue for increasing vascularity
CN111902393B (en) 2018-05-15 2023-11-10 旭化成株式会社 Method for producing amino acid aminoalkyl ester or inorganic acid salt thereof
CN111468183A (en) * 2019-11-25 2020-07-31 天津大学 Polyfluorinated triaryl chiral spirophosphoric acid catalyst and preparation method and use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0031088A1 (en) * 1979-12-19 1981-07-01 Hoechst Aktiengesellschaft Benzene-sulfonyl ureas, processes for their preparation, pharmaceutical compositions based on these compounds and their use
ES2081747B1 (en) * 1993-09-07 1997-01-16 Esteve Labor Dr AMIDES DERIVED FROM TIENOPIRROLES, THEIR PREPARATION AND THEIR APPLICATION AS MEDICINES.
FR2733750B1 (en) * 1995-05-03 1997-06-13 Synthelabo DERIVATIVES OF GAMMA-OXO-ALPHA- (PHENYLMETHYL) -5,6- DIHYDRO-4H-THIENO (3,4-C) PYRROLE-5-BUTANOIQUE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
AP9600817A0 (en) * 1995-06-06 1996-07-31 Pfizer Novel cryatal form of anhydrous 7-( [1A,5A,6A]-6-amino3-3-azabicyclo [3.1.0.] hex-3-yl) -6-fluro-1-(2,4-difluorophenyl)-1,4-dihydro-4-oxo-1, 8-naphthyridine-3-carboxylic acid, methanesulfonic acid salt.
US5952322A (en) * 1996-12-05 1999-09-14 Pfizer Inc. Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors
PT901786E (en) * 1997-08-11 2007-08-07 Pfizer Prod Inc Solid pharmaceutical dispersions with enhanced bioavailability
US5939417A (en) * 1998-10-19 1999-08-17 Cell Pathways Inc 1,3,6-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia

Also Published As

Publication number Publication date
ES2211454T3 (en) 2004-07-16
ATE257480T1 (en) 2004-01-15
DK1088824T3 (en) 2004-04-13
US20020183369A1 (en) 2002-12-05
JP2001131181A (en) 2001-05-15
BR0004582A (en) 2001-04-17
CA2321379A1 (en) 2001-03-30
DE60007592T2 (en) 2004-09-16
EP1088824A2 (en) 2001-04-04
JP3489819B2 (en) 2004-01-26
US6399601B1 (en) 2002-06-04
EP1088824A3 (en) 2001-06-27
US20030195361A1 (en) 2003-10-16
US6576653B2 (en) 2003-06-10
EP1088824B1 (en) 2004-01-07
US6828343B2 (en) 2004-12-07
DE60007592D1 (en) 2004-02-12

Similar Documents

Publication Publication Date Title
PT1088824E (en) 2004-04-30 BLYCYLIC PYRROLYL-AMIDES AS GLYCOGENE-PHOSPHORYLASE INHIBITORS
MXPA05011702A (en) 2006-01-23 Anti-diabetic agents.
BR0316099A (en) 2005-09-27 Antidiabetic Agents
EA200970585A1 (en) 2009-10-30 BENZAMIDE DERIVATIVES AS AGONISTS OF EP RECEPTORS
PT1349843E (en) 2005-09-30 TIAZOL AND OXAZOLE DERIVATIVES AS ACTIVATORS OF RECEPTORS ACTIVATED BY HUMAN PEROXYSTOM PROLIFERATORS
BR0000968A (en) 2000-09-19 oxamic acids containing cyano and its derivatives as ligands for thyroid receptors
EE200300403A (en) 2003-12-15 N-substituted Non-Aromatic Heterocyclic Compound, Pharmaceutical Composition Containing It, and Use of the Compound as a Pharmaceutical
CY1105631T1 (en) 2010-12-22 SUBSTITUTED CARBOSTYRYL DERIVATIVES AS 5-HT1A RECEPTOR SUBTYPE AGENTS
WO2007039883A3 (en) 2007-08-02 Process for preparation of aprepitant
ATE523498T1 (en) 2011-09-15 HIV-INHIBITING 2-(4-CYANOPHENYLAMINO)PYRIMIDINE DERIVATIVES
NO20032261D0 (en) 2003-05-20 Medical preparations
NO20052908L (en) 2005-09-12 Aromatic compounds as anti-inflammatory, immunomodulatory and anti-proliferative agents.
EP1914229A4 (en) 2009-03-18 NEW CERCOSPORAMIDE DERIVATIVE
WO2006059164A3 (en) 2006-08-17 Pyrrolopyridine-2-carboxylic acid amides
EA200870223A1 (en) 2009-02-27 DERIVATIVES OF BENZOIZOINDOL FOR THE TREATMENT OF PAIN
ATE511506T1 (en) 2011-06-15 THIOPENE DERIVATIVES AS ACTIVE INGREDIENTS AGAINST OCCULAR HYPOTONIA
BR0200536A (en) 2003-04-29 Sulfonylpyridazinane compounds useful as aldose reductase inhibitors
BRPI0411208A (en) 2006-07-18 use of 2-amino-1,3-propanediol derivatives for the manufacture of a medicament for the treatment of various types of pain
DK1179342T3 (en) 2006-07-31 Medicinal compositions for immediate release by oral use
BRPI0406990A (en) 2006-01-10 Oligosaccharide derivative
SI1924255T1 (en) 2011-02-28 Use of n-(dibenz (b,f)oxepin-10-ylmethyl)-n-methyl-n-prop-2-ynylamine (omigapil) for the prophylaxis and/or treatment of muscular dystrophy
TW200642686A (en) 2006-12-16 Aporphine or secoaporphine compounds for treatment of diabetes
ZA200710662B (en) 2008-11-26 1-[2&#39;, 3&#39;-dideoxy-3&#39; C-(hydroxymethyl)-beta-d-erythropentofuranosyl] cytosine derivatives as HIV inhibitors